Hematopoietic Innovative Therapies
“CIEMAT’s Hematopoietic Innovative Therapies group is focused on the development of translational research to improve the diagnosis and treatment of inherited and acquired pathologies through genetic, molecual and cellular biology techniques”
News
- Investigadora del CIEMAT formará parte del Comité Científico Asesor de la Fanconi Anemia Research Foundation
- Células mesenquimales, soluciones para mejorar su eficacia.
- Un nuevo modelo celular de disqueratosis congénita ayudará a comprender la enfermedad y evaluar nuevas terapias
- Nuevos logros de la Unidad Mixta de Terapias Avanzadas CIEMAT-FIIS-FJD
- Un proyecto de terapia génica para la trombastenia de Glanzmann, dotado con 50.000 euros de la EAHAD
Fanconi Anemia
A gene therapy clinical trial for patients with Fanconi Anemia offers its first successful results
Dyskeratosis Congenita
A new cell model of dyskeratosis congenita will help understand the disease and evaluate new therapies
LAD-I immunodeficiency
First successful results in gene therapy in a patient with LAD-I immunodeficiency
